China Pharma Holdings, Inc.
CPHI
$1.43
$0.0151.06%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.91% | -17.05% | -47.25% | -39.00% | -15.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.91% | -17.05% | -47.25% | -39.00% | -15.76% |
| Cost of Revenue | -42.65% | -23.35% | -41.91% | -20.47% | 55.91% |
| Gross Profit | 91.43% | 53.07% | -102.78% | -122.81% | -592.16% |
| SG&A Expenses | 156.94% | -0.27% | 8.05% | 9.99% | -25.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.07% | -17.10% | -30.12% | -13.17% | 49.05% |
| Operating Income | 63.97% | 17.19% | -0.97% | -52.11% | -204.95% |
| Income Before Tax | 63.26% | 17.82% | 0.63% | -43.76% | -142.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 63.26% | 17.82% | 0.63% | -43.76% | -142.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 63.26% | 17.82% | 0.63% | -43.76% | -142.51% |
| EBIT | 63.97% | 17.19% | -0.97% | -52.11% | -204.95% |
| EBITDA | 72.31% | -135.49% | -53.06% | -1,177.30% | -373.50% |
| EPS Basic | 81.84% | 66.42% | 68.65% | 78.04% | 74.58% |
| Normalized Basic EPS | 81.84% | 66.42% | 68.64% | 78.04% | 74.59% |
| EPS Diluted | 81.84% | 66.42% | 68.65% | 78.04% | 74.58% |
| Normalized Diluted EPS | 81.84% | 66.42% | 68.64% | 78.04% | 74.59% |
| Average Basic Shares Outstanding | 102.31% | 144.69% | 216.92% | 554.82% | 854.08% |
| Average Diluted Shares Outstanding | 102.31% | 144.69% | 216.92% | 554.82% | 854.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |